Gynesonics® announced Anthem, Inc. has provided positive payer coverage for the Sonata® Treatment. Anthems decision creates access for this minimally invasive procedure for women across the country, having the largest impact in California, New York, Georgia, Ohio, Virginia and Indiana. The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is an alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes and locations. Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved. Anthem is one of the countrys largest healthcare insurance plans and this policy validates the need for less invasive treatment options for women with systematic fibroids. Currently in the U.S. women will wait 3-5 years for treatment trying to avoid invasive surgery. As well, black women have the highest incidence of fibroid diagnoses, yet studies show they are least likely to be offered less invasive treatment options.